Mirum Pharmaceuticals (MIRM) Net Income towards Common Stockholders (2019 - 2026)

Mirum Pharmaceuticals' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$790.2 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 5283.63% year-over-year to -$790.2 million; the TTM figure through Mar 2026 stood at -$798.8 million (down 932.9% YoY), while the FY2025 annual figure was -$23.4 million, up 73.43% from the prior year.
• Net Income towards Common Stockholders was -$790.2 million for Q1 2026 at Mirum Pharmaceuticals, down from -$5.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $2.9 million in Q3 2025 to a low of -$790.2 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$70.6 million across 5 years, with a median of -$25.3 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders jumped 120.41% in 2025, then sank 5283.63% in 2026.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$36.4 million in 2022, then increased by 2.12% to -$35.7 million in 2023, then surged by 33.28% to -$23.8 million in 2024, then soared by 75.91% to -$5.7 million in 2025, then plunged by 13689.79% to -$790.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$790.2 million (Q1 2026), -$5.7 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.